3B Future Health Fund

3B Future Health Fund focuses on early-stage investment opportunities in the field of oncology and rare disease therapeutics, based in the US and Europe. The firm seeks to bring life-changing treatments to patients by supporting companies with potential first-in-class assets, revolutionary insights, experienced management teams, and a strong investor syndicate. They typically invest in Series A rounds, but may invest earlier in some cases. The fund leverages the team's extensive experience in drug discovery, R&D, drug manufacturing, business development, licensing, and investment fund management to actively participate in the strategic management of their portfolio companies, sharing their experience and network to build value. The firm is guided by core values of Quality, Integrity, and Respect, prioritizing companies that share a strong passion for bringing new life-changing treatments to patients. They look for opportunities where there are high unmet patient needs, demonstrating a commitment to impacting patient lives. The firm's mission is to be the preferred partner to select investors and portfolio companies, driven by a sense of purpose, excellent execution, personal involvement, and premium performance. 3B Future Health Fund aims to build a diversified portfolio by investing in companies at early and mid-stages of development, taking into account different levels of complexity in science and technology, with a drug modality agnostic approach. With a 10-year fund structure, investments are held for five to eight years, or fewer if value inflection points are reached which could permit earlier exits. The fund intends to invest in 10-15 companies, with up to $12 million investment in each and Board positions.

Oncology, Rare Diseases Therapeutics

Core thematic spaces, technologies, and target market segments of interest.